natgillin/translations-raw huggingface dataset:
Zda jsou splněny podmínky uvedené v čl.
For the purposes of Article 9(3), third countries listed in Annex I to Commission Implementing Decision 2014/908/EU [1] are deemed to be equivalent.
400 odst.
Credit institutions must take the following criteria into account when assessing whether an exposure referred to in Article 400(2)(c) of Regulation (EU) No 575/2013 meets the conditions for an exemption from the large exposure limit, in accordance with Article 400(3) of Regulation (EU) No 575/2013.
3 nařízení (EU) č. 575/2013 a v příslušné příloze tohoto nařízení, které jsou použitelné na konkrétní expozici, posuzují úvěrové instituce.
For the purpose of assessing whether the specific nature of the exposure, the counterparty or the relationship between the credit institution and the counterparty eliminate or reduce the risk of the exposure, as provided for in Article 400(3)(a) of Regulation (EU) No 575/2013, credit institutions must take into account whether:
ECB může toto posouzení kdykoli ověřit a může úvěrové instituce požádat, aby jí za tímto účelem předložily dokumentaci uvedenou v příslušné příloze.
the conditions provided for in Article 113(6)(b), (c) and (e) of Regulation (EU) No 575/2013 are met and in particular whether the counterparty is subject to the same risk evaluation, measurement and control procedures as the credit institution and whether the IT systems are integrated or, at least, fully aligned.
Tento článek se uplatní pouze v případě, kdy příslušný členský stát neuplatnil možnost udělit částečně nebo v plném rozsahu výjimku pro konkrétní expozice, stanovenou v čl.
In addition, they must take into account whether there are any current or anticipated material practical or legal impediments that would hinder the timely repayment of the exposure by the counterparty to the credit institution, other than in the event of a recovery or resolution situation when the restrictions outlined in Directive 2014/59/EU of the European Parliament and of the Council [2] are required to be implemented;
493 odst.
the proposed intragroup exposures are justified by the group's funding structure;
3 nařízení (EU) č. 575/2013.
the process by which a decision is made to approve an exposure to the intragroup counterparty, and the monitoring and review process applicable to such exposures, at individual level and at consolidated level, where relevant, are similar to those that are applied to third party lending;
KAPITOLA IV
the credit institution's risk management procedures, IT system and internal reporting enable it to continuously check and ensure that large exposures to group undertakings are aligned with its risk strategy at legal entity level and at consolidated level, where relevant.
LIKVIDITA
For the purpose of assessing whether any remaining concentration risk can be addressed by other equally effective means such as the arrangements, processes and mechanisms provided for in Article 81 of Directive 2013/36/EU, as provided for in Article 400(3)(b) of Regulation (EU) No 575/2013, credit institutions must take into account whether:
Článek 10
the credit institution has robust processes, procedures and controls, at individual level and at consolidated level, where relevant, to ensure that use of the exemption would not result in concentration risk that is outside its risk strategy and against the principles of sound internal liquidity management within the group;
Čl.
the credit institution has formally considered the concentration risk arising from intragroup exposures as part of its overall risk assessment framework;
415 odst.
the credit institution has a risk control framework, at legal entity level and at consolidated level where relevant, that adequately monitors the proposed exposures;
3 nařízení (EU) č. 575/2013: Povinnost podávat zprávy
the concentration risk arising has been or will be clearly identified in the internal capital adequacy assessment process (ICAAP) of the credit institution and will be actively managed.
Aniž by byla dotčena jiná zpravodajská povinnost a pokud tyto informace nebyly vnitrostátním příslušným orgánům již poskytnuty, předávají úvěrové instituce v souladu s čl.
The arrangements, processes and mechanisms to manage the concentration risk will be assessed in the supervisory review and evaluation process;
415 odst.
there is evidence that the management of concentration risk is consistent with the group's recovery plan.
3 nařízení (EU) č. 575/2013 ECB informace, které jsou podle vnitrostátních právních předpisů vyžadovány pro účely sledování souladu s vnitrostátními standardy platnými pro likviditu.
For the purposes of verifying whether the conditions specified in paragraph 1 and 2 are met, the European Central Bank may request credit institutions to submit the following documentation.
Článek 11
A letter signed by the credit institution's legal representative, with approval from the management body, stating that the credit institution complies with all the conditions for an exemption as laid down in Article 400(2)(c) and Article 400(3) of Regulation (EU) No 575/2013.
Čl.
A legal opinion, issued either by an external independent third party or by an internal legal department, and approved by the management body, demonstrating that there are no obstacles that would hinder timely repayment of exposures by a counterparty to the credit institution that arise from either applicable regulations, including fiscal regulations, or binding agreements.
420 odst.
A statement signed by the legal representative and approved by the management body stating that:
2 nařízení (EU) č. 575/2013 a čl.
there are no practical impediments that would hinder the timely repayment of exposures by a counterparty to the credit institution;
23 odst.
intragroup exposures are justified by the group's funding structure;
2 nařízení v přenesené pravomoci (EU) 2015/61: Odtok likvidity
the process by which a decision is made to approve an exposure to an intragroup counterparty and the monitoring and review process applicable to such exposures, at legal entity level and at consolidated level, are similar to those that are applied to third-party lending;
Při posuzování odtoku likvidity v důsledku podrozvahových položek týkajících se financování obchodu, jak je uvedeno v čl. 420 odst.
concentration risk arising from intragroup exposures has been considered as part of the credit institution's overall risk assessment framework.
2 a v příloze I nařízení (EU) č. 575/2013, a dokud ECB neurčí konkrétní sazby odtoku podle čl.
Documentation signed by the legal representative and approved by the management body attesting that the credit institution's risk evaluation, measurement and control procedures are the same as the counterparty's and that the credit institution's risk management procedures, IT system and internal reporting enable the management body to continuously monitor the level of the large exposure and its compatibility with the credit institution's risk strategy at legal entity level and at consolidated level, where relevant, and with the principles of sound internal liquidity management within the group.
23 odst.
Documentation showing that the ICAAP clearly identifies the concentration risk arising from the large intragroup exposures and that this risk is actively managed.
2 nařízení v přenesené pravomoci (EU) 2015/61, uplatní úvěrové instituce sazbu odtoku ve výši 5 %, jak je uvedeno v čl. 420 odst.
Documentation showing that the management of concentration risk is consistent with the group's recovery plan.
2 uvedeného nařízení a v čl.
Commission Implementing Decision 2014/908/EU of 12 December 2014 on the equivalence of the supervisory and regulatory requirements of certain third countries and territories for the purposes of the treatment of exposures according to Regulation (EU) No 575/2013 of the European Parliament and of the Council (OJ L 359, 16.12.2014, p. 155).
23 odst.
Directive 2014/59/EU of the European Parliament and of the Council of 15 May 2014 establishing a framework for the recovery and resolution of credit institutions and investment firms and amending Council Directive 82/891/EEC, and Directives 2001/24/EC, 2002/47/EC, 2004/25/EC, 2005/56/EC, 2007/36/EC, 2011/35/EU, 2012/30/EU and 2013/36/EU, and Regulations (EU) No 1093/2010 and (EU) No 648/2012, of the European Parliament and of the Council (OJ L 173, 12.6.2014, p. 190).
2 nařízení v přenesené pravomoci (EU) 2015/61.
ANNEX II
Odpovídající odtok se vykazuje v souladu s prováděcím nařízením Komise (EU) č. 680/2014 [8].Článek 12
Conditions for assessing an exemption from the large exposure limit, in accordance with Article 400(2)(d) of Regulation (EU) No 575/2013 and Article 9(4) of this Regulation
Čl.
Credit institutions must take the following criteria into account when assessing whether an exposure referred to in Article 400(2)(d) of Regulation (EU) No 575/2013 meets the conditions for an exemption from the large exposure limit, in accordance with Article 400(3) of Regulation (EU) No 575/2013.
12 odst.
For the purpose of assessing whether the specific nature of the exposure, the regional or central body or the relationship between the credit institution and the regional or central body eliminate or reduce the risk of the exposure, as provided for in Article 400(3)(a) of Regulation (EU) No 575/2013, credit institutions must take into account whether:
3 nařízení v přenesené pravomoci (EU) 2015/61: Aktiva úrovně 2B
there are any current or anticipated material practical or legal impediments that would hinder the timely repayment of the exposure by the counterparty to the credit institution, other than in the event of a recovery or resolution situation, when the restrictions outlined in the Directive 2014/59/EU are required to be implemented;
Úvěrové instituce, které v souladu se svými stanovami nemohou z náboženských důvodů držet úročená aktiva, mohou jako likvidní aktiva úrovně 2B zahrnout korporátní dluhové cenné papíry v souladu se všemi podmínkami uvedenými v čl.
the proposed exposures are in line with the credit institution's ordinary course of business and its business model or justified by the funding structure of the network;
12 odst.
the process by which a decision is made to approve an exposure to the credit institution's central body, and the monitoring and review process applicable to such exposures, at individual level and at consolidated level, where relevant, are similar to those that are applied to third-party lending;
1 písm. b) včetně odrážek ii) a iii) nařízení v přenesené pravomoci (EU) 2015/61.
the credit institution's risk management procedures, IT system and internal reporting enable it to continuously check and ensure that the large exposures to its regional or central body are compatible with its risk strategy.
V případě úvěrových institucí uvedených v odstavci 1 může ECB pravidelně přezkoumávat požadavek uvedený v daném odstavci a umožnit odchylku od použití čl.
For the purpose of assessing whether any remaining concentration risk can be addressed by other equally effective means such as the arrangements, processes and mechanisms provided for in Article 81 of Directive 2013/36/EU, as provided for in Article 400(3)(b) of Regulation (EU) No 575/2013, credit institutions must take into account whether:
12 odst.
the credit institution has robust processes, procedures and controls to ensure that use of the exemption would not result in concentration risk which is outside its risk strategy;
1 písm. b) odrážka ii) a iii) nařízení v přenesené pravomoci (EU) 2015/61, jsou-li splněny podmínky uvedené v čl.
the credit institution has formally considered the concentration risk arising from exposures to its regional or central body as part of its overall risk assessment framework;
12 odst.
the credit institution has a risk control framework that adequately monitors the proposed exposures;
3 uvedeného nařízení v přenesené pravomoci.
the concentration risk arising has been or will be clearly identified in the credit institution's internal capital adequacy assessment process (ICAAP) and will be actively managed.
Článek 13
The arrangements, processes and mechanisms to manage the concentration risk will be assessed in the supervisory review and evaluation process.
Čl.
In addition to the conditions set out in paragraph 1, credit institutions must take into account, for the purpose of assessing whether the regional or central body with which the credit institution is associated in a network is responsible for cash-clearing operations, as provided for in Article 400(2)(d) of Regulation (EU) No 575/2013, whether the by-laws or articles of association of the regional or central body explicitly contain such responsibilities, including, but not limited to the following:
24 odst.
market funding for the whole network;
4 a 5 nařízení v přenesené pravomoci (EU) 2015/61: Odtok stabilních retailových vkladů
clearing liquidity within the network, within the scope of in Article 10 of Regulation (EU) No 575/2013;
Úvěrové instituce sazbou ve výši 3 % vynásobí objem stabilních retailových vkladů, které jsou kryty systémem pojištění vkladů, jak je uvedeno v čl.
providing liquidity to affiliated credit institutions;
24 odst.
absorbing excess liquidity of affiliated credit institutions.
4 nařízení v přenesené pravomoci (EU) 2015/61, za předpokladu, že Komise v souladu s čl.
A letter signed by the credit institution's legal representative, with approval from the management body, stating that the credit institution complies with all the conditions laid down in Article 400(2)(d) and Article 400(3) of Regulation (EU) No 575/2013 for an exemption to be granted.
24 odst.
A legal opinion, issued either by an external independent third party or by an internal legal department, and approved by the management body, demonstrating that there are no obstacles that would hinder the timely repayment of exposures by a regional or central body to the credit institution arising from either applicable regulations, including fiscal regulations, or binding agreements.
5 uvedeného nařízení v přenesené pravomoci vydala předchozí souhlas, který potvrzuje, že jsou splněny všechny podmínky uvedené v čl.
A statement signed by the legal representative and approved by the management body that:
24 odst.
there are no practical impediments to the timely repayment of exposures by a regional or central body to the credit institution;
4.
the regional or central body exposures are justified by the funding structure of the network;
KAPITOLA V
the process by which a decision is made to approve an exposure to a regional or central body and the monitoring and review process applicable to such exposures, at legal entity level and at consolidated level, are similar to those applied to third-party lending;
PŘECHODNÁ USTANOVENÍ NAŘÍZENÍ (EU) Č. 575/2013
the concentration risk arising from exposures to the regional or central body has been considered as part of the credit institution's overall risk assessment framework.
Článek 14
Documentation signed by the legal representative and approved by the management body attesting that the credit institution's risk evaluation, measurement and control procedures are the same as the regional or central body's and that the credit institution's risk management procedures, IT system and internal reporting enable the management body to continuously monitor the level of the large exposure and its compatibility with the credit institution's risk strategy at legal entity level and at consolidated level, where relevant, and with the principles of sound internal liquidity management within the network.
Čl.
Documentation showing that the ICAAP clearly identifies the concentration risk arising from the large exposures to the regional or central body and that this is actively managed.
467 odst.
Documentation showing that the management of concentration risk is consistent with the network's recovery plan.
Nařízení Komise (EU) 2016/452
Commission Regulation (EU) 2016/452
kterým se mění přílohy II a III nařízení Evropského parlamentu a Rady (ES) č. 396/2005, pokud jde o maximální limity reziduí pro kaptan, propikonazol a spiroxamin v některých produktech a na jejich povrchu
amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for captan, propiconazole and spiroxamine in or on certain products
s ohledem na nařízení Evropského parlamentu a Rady (ES) č. 396/2005 ze dne 23. února 2005 o maximálních limitech reziduí pesticidů v potravinách a krmivech rostlinného a živočišného původu a na jejich povrchu a o změně směrnice Rady 91/414/EHS [1], a zejména na čl. 14 odst. 1 písm. a) a čl. 49 odst. 2 uvedeného nařízení,
Having regard to Regulation (EC) No 396/2005 of the European Parliament and of the Council of 23 February 2005 on maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC [1], and in particular Article 14(1)(a) and Article 49(2) thereof,
Maximální limity reziduí (MLR) pro kaptan, propikonazol a spiroxamin byly stanoveny v příloze II a příloze III části B nařízení (ES) č. 396/2005.
For captan, propiconazole and spiroxamine, maximum residue levels (MRLs) were set in Annex II and Part B of Annex III to Regulation (EC) No 396/2005.
Pokud jde o kaptan, předložil Evropský úřad pro bezpečnost potravin (dále jen „úřad“) odůvodněné stanovisko ke stávajícím MLR v souladu s čl. 12 odst. 2 nařízení (ES) č. 396/2005 ve spojení s čl. 12 odst. 1 uvedeného nařízení [2].
For captan, the European Food Safety Authority, hereinafter ‘the Authority’, submitted a reasoned opinion on the existing MRLs in accordance with Article 12(2) of Regulation (EC) No 396/2005 in conjunction with Article 12(1) thereof [2].
Navrhl změnit definici rezidua pro rostlinné komodity.
It proposed to change the residue definition for plant commodities.
Úřad dospěl k závěru, že pokud jde o MLR pro jablka, hrušky, kdoule, mišpuli obecnou/německou, mišpuli japonskou/lokvát, meruňky, třešně, broskve, švestky, jahody, ostružiny, maliny, borůvky, rybíz, angrešt a rajčata, nejsou některé informace k dispozici a je nezbytné, aby subjekty, které se zabývají řízením rizika, provedly další posouzení.
It concluded that concerning the MRLs for apples, pears, quinces, medlar, loquat, apricots, cherries, peaches, plums, strawberries, blackberries, raspberries, blueberries, currants, gooseberries and tomatoes some information was not available and that further consideration by risk managers was required.
Vzhledem k tomu, že neexistuje žádné riziko pro spotřebitele, měly by být MLR pro tyto produkty stanoveny v příloze II nařízení (ES) č. 396/2005 na stávající úrovni nebo na úrovni určené úřadem.
As there is no risk for consumers, the MRLs for these products should be set in Annex II to Regulation (EC) No 396/2005 at the existing level or the level identified by the Authority.
Tyto MLR budou přezkoumány; přezkum zohlední informace dostupné během dvou let od vyhlášení tohoto nařízení.
These MRLs will be reviewed; the review will take into account the information available within 2 years from the publication of this Regulation.
Úřad dospěl k závěru, že pokud jde o MLR pro mandle, hrozny stolní, hrozny moštové, brambory, okurky salátové, melouny cukrové, endivii, pór, kukuřici a čirok, nejsou k dispozici žádné informace a že je nezbytné, aby subjekty, které se zabývají řízením rizika, provedly další posouzení.
The Authority concluded that concerning the MRLs for almonds, table grapes, wine grapes, potatoes, cucumbers, melons, scarole, leek, maize and sorghum no information was available and that further consideration by risk managers was required.
Pokud jde o propikonazol, předložil úřad odůvodněné stanovisko ke stávajícím MLR v souladu s čl. 12 odst. 2 nařízení (ES) č. 396/2005 ve spojení s čl. 12 odst. 1 uvedeného nařízení [3].
For propiconazole, the Authority submitted a reasoned opinion on the existing MRLs in accordance with Article 12(2) of Regulation (EC) No 396/2005 in conjunction with Article 12(1) thereof [3].
Úřad dospěl k závěru, že pokud jde o MLR pro grapefruity, citrony, kyselé lajmy, mandarinky, jablka, meruňky, hrozny stolní a moštové, banány, semena řepky olejky, zrna ječmene, zrna ovsa, zrna rýže, zrna žita, zrna pšenice, řepu cukrovku (kořen), svalovinu a tuk prasat, svalovinu a tuk skotu, svalovinu a tuk ovcí, svalovinu a tuk koz, svalovinu a tuk drůbeže, kravské, ovčí a kozí mléko a ptačí vejce, nejsou některé informace k dispozici a je nezbytné, aby subjekty, které se zabývají řízením rizika, provedly další posouzení.
It concluded that concerning the MRLs for grapefruit, lemons, limes, mandarins, apples, apricots, table and wine grapes, bananas, rape seed, barley grain, oats grain, rice grain, rye grain, wheat grain, sugar beet (root), swine muscle and fat, bovine muscle and fat, sheep muscle and fat, goat muscle and fat, poultry muscle and fat, cattle, sheep and goat milk and birds' eggs some information was not available and that further consideration by risk managers was required.
Pokud jde o MLR pro mandle, třešně, švestky, jahody, rybíz (bílý, černý, červený), angrešt, papriku, okurky salátové, artyčoky, jádra podzemnice olejné a čaj, dospěl úřad k závěru, že nejsou k dispozici žádné informace a že je nezbytné, aby subjekty, které se zabývají řízením rizika, provedly další posouzení.
The Authority concluded that concerning the MRLs for almonds, cherries, plums, strawberries, currants (red, black and white), gooseberries, peppers, cucumbers, globe artichokes, peanuts and tea no information was available, and that further consideration by risk managers was required.
Pokud jde o spiroxamin, předložil úřad odůvodněné stanovisko ke stávajícím MLR v souladu s čl. 12 odst. 2 nařízení (ES) č. 396/2005 ve spojení s čl. 12 odst. 1 uvedeného nařízení [4].
For spiroxamine, the Authority, submitted a reasoned opinion on the existing MRLs in accordance with Article 12(2) of Regulation (EC) No 396/2005 in conjunction with Article 12(1) thereof [4].
Úřad navrhl změnit definici rezidua a dospěl k závěru, že pokud jde o MLR pro hrozny stolní a moštové, banány, ječmen, oves, žito, pšenici, svalovinu, tuk a játra drůbeže a ptačí vejce, nejsou některé informace k dispozici a je nezbytné, aby subjekty, které se zabývají řízením rizika, provedly další posouzení.
It proposed to change the residue definition and concluded that concerning the MRLs for table and wine grapes, banana, barley, oats, rye, wheat, poultry muscle, fat and liver and birds' eggs some information was not available and that further consideration by risk managers was required.
Tyto MLR budou přezkoumány; přezkum zohlední informace dostupné během dvou let od vyhlášení tohoto nařízení.
These MRLs will be reviewed; the review will take into account the information available within 2 years from the publication of this Regulation.
Jelikož je vhodné stanovit definici rezidua pro komodity živočišného původu jako „metabolit M06 spiroxamin-karboxylové kyseliny, vyjádřeno jako spiroxamin (suma izomerů)“, je dostupný dostatek informací pro stanovení MLR pro svalovinu, tuk, játra a ledviny prasat, svalovinu, tuk, játra a ledviny skotu, svalovinu, tuk, játra a ledviny ovcí, svalovinu, tuk, játra a ledviny koz a kravské, ovčí a kozí mléko.
As it is appropriate to set the residue definition for animal origin commodities as ‘spiroxamine carboxylic acid metabolite M06, expressed as spiroxamine (sum of isomers)’, sufficient information is available for setting MRLs for swine muscle, fat, liver and kidney, bovine muscle, fat, liver and kidney, sheep muscle, fat, liver and kidney, goat muscle, fat, liver and kidney, cattle, sheep and goat milk.
Jelikož MLR pro ječmen a oves ve výši 0,4 mg/kg jsou založeny na správné zemědělské praxi, která již není podporována, měly by být MLR pro tyto komodity sníženy na 0,05 mg/kg.
As the MRLs for barley and oats of 0,4 mg/kg are based on a good agricultural practice that is no longer supported, the MRLs for those commodities should be reduced to 0,05 mg/kg.